Nexien Biopharma (NXEN) Stock Price, News & Analysis

Company Overview

Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.

Key Stats

• Today's Range: $0.0057 to $0.0057
• 50-Day Range: $0.0056 to $0.0145
• 52-Week Range: $0.00 to $0.05
• Volume: 1,504 shs
• Average Volume: 13,542 shs
• Market Capitalization: $403.39 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NXEN Stock Analysis - Frequently Asked Questions

How have NXEN shares performed this year?

NEXIEN BIOPHARMA's stock was trading at $0.0056 at the start of the year. Since then, NXEN shares have increased by 1.8% and is now trading at $0.0057.
View the best growth stocks for 2025 here.

How do I buy shares of NEXIEN BIOPHARMA?

Shares of NXEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NEXIEN BIOPHARMA own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NEXIEN BIOPHARMA investors own include Labor Smart (LTNC), Acrivon Therapeutics (ACRV), Heatwurx (PCSA), Aurora Innovation (AUR), NVIDIA (NVDA), American Cannabis (AMMJ) and American Noble Gas (AMNI).

Company Calendar

• Today: 6/24/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:NXEN
• CIK: 1625288
• Web: www.nexienbiopharma.com
• Phone: (303) 495-7583
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$240 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -4,015.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.02
• Quick Ratio: 0.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.01) per share
• Price / Book: -0.57

Miscellaneous

• Outstanding Shares: 70,770,000
• Free Float: 49,116,000
• Market Cap: $403.39 thousand
• Optionable: Not Optionable
• Beta: -0.58